Literature DB >> 15274408

Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.

Norio Yukawa1, Takaki Yoshikawa, Makoto Akaike, Yukio Sugimasa, Shoji Takemiya, Shunsuke Yanoma, Toshio Imada, Yoshikazu Noguchi.   

Abstract

BACKGROUND: Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in plasma has been reported to be related to disease progression in patients with colorectal cancer. However, the prognostic significance of plasma TIMP-1 has not been clarified. PATIENTS AND METHODS: Concentrations of TIMP-1 protein were measured by enzyme-linked immunosorbent assay in plasma samples of 87 preoperative patients who subsequently underwent resection, and prognosis was compared. The cut-off value of plasma TIMP-1 was defined as 170 ng/ml.
RESULTS: When clinicopathological factors between patients with positive and those with negative plasma TIMP-1 were analyzed, significant differences were observed in lymph node metastasis, serosal invasion, curability and Dukes' classification. Univariate analysis of these factors demonstrated that depth of invasion, metastases to lymph nodes, peritoneum, liver and distant organ, lymphatic and vessel invasions, curability. Dukes' classification and plasma TIMP-1 concentration were significant. By multivariate analysis excluding patients with distant or peritoneal metastases, histological type, lymphatic invasions, lymph node metastasis and plasma TIMP-1 were retained in the final model.
CONCLUSION: These results suggested that plasma TIMP-1 may be a useful prognostic marker for survival in patients with colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274408

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.

Authors:  Markus Wagner; Vincent Roh; Michael Strehlen; Alexander Laemmle; Deborah Stroka; Bernhard Egger; Markus Trochsler; Kelly K Hunt; Daniel Candinas; Stephan A Vorburger
Journal:  J Gastrointest Surg       Date:  2009-06-30       Impact factor: 3.452

2.  Protein levels of tissue inhibitor of metalloproteinase-1 in tumor extracts as a marker for prognosis and recurrence in patients with gastric cancer.

Authors:  Takaki Yoshikawa; Akira Tsuburaya; Osamu Kobayashi; Motonori Sairenji; Yohei Miyagi
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

3.  TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.

Authors:  Karen-Lise Garm Spindler; Ib Jarle Christensen; Hans Jørgen Nielsen; Anders Jakobsen; Nils Brünner
Journal:  Tumour Biol       Date:  2015-01-23

4.  The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients.

Authors:  Barbara Mroczko; Magdalena Groblewska; Bogna Okulczyk; Bogusław Kedra; Maciej Szmitkowski
Journal:  Int J Colorectal Dis       Date:  2010-06-17       Impact factor: 2.571

5.  TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis.

Authors:  M L Davidsen; S Ø Würtz; M U Rømer; N M Sørensen; S K Johansen; I J Christensen; J K Larsen; H Offenberg; N Brünner; U Lademann
Journal:  Br J Cancer       Date:  2006-10-23       Impact factor: 7.640

6.  Prognostic significance of tissue inhibitor of metalloproteinase-1 in breast cancer.

Authors:  Arunee Dechaphunkul; Monlika Phukaoloun; Kanet Kanjanapradit; Kathryn Graham; Sunita Ghosh; Cheryl Santos; John R Mackey
Journal:  Int J Breast Cancer       Date:  2012-09-04

7.  High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.

Authors:  A Gaber; M Johansson; U-H Stenman; K Hotakainen; F Pontén; B Glimelius; A Bjartell; K Jirström; H Birgisson
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

8.  TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer.

Authors:  Line S Tarpgaard; Maj Sofie Ørum-Madsen; Ib J Christensen; Cathrine Nordgaard; Julie Noer; Tormod K Guren; Bengt Glimelius; Halfdan Sorbye; Tone Ikdahl; Elin H Kure; Kjell M Tveit; Hans J Nielsen; Per Pfeiffer; Nils Brünner; José M A Moreira
Journal:  Oncotarget       Date:  2016-09-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.